



## UroGen Pharma to Present at Upcoming Investor Conferences

August 31, 2023

PRINCETON, N.J.--(BUSINESS WIRE)--Aug. 31, 2023-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced that it will present at the following investor conferences in September:

### H.C. Wainwright 25th Annual Global Investment Conference —September 11-13, 2023

- Presentation: Tuesday, September 12<sup>th</sup> at 10:00 AM ET
- Webcast Link: <https://journey.ct.events/view/b77088e1-4859-49a5-bdbe-353a3774b1ba>

### 2023 Cantor Fitzgerald Global Healthcare Conference —September 26 - 28, 2023

- Fireside Chat: Tuesday, September 26<sup>th</sup> at 8:35 AM ET
- Webcast Link: <https://wsw.com/webcast/cantor19/urgn/2115036>

Webcasts for both conferences will be available via the Investors section of UroGen's website, [www.urogen.com](http://www.urogen.com). A replay of each webcast will be available on the Company's website for approximately 90 days.

### About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. JELMYTO® (mitomycin) for pyelocalyceal solution and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit [www.urogen.com](http://www.urogen.com) to learn more or follow us on Twitter, @UroGenPharma.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20230831174677/en/): <https://www.businesswire.com/news/home/20230831174677/en/>

### INVESTOR CONTACT:

Vincent Perrone  
Senior Director, Investor Relations  
[vincent.perrone@urogen.com](mailto:vincent.perrone@urogen.com)  
609-460-3588 ext. 1093

### MEDIA CONTACT:

Cindy Romano  
Director, Corporate Communications  
[cindy.romano@urogen.com](mailto:cindy.romano@urogen.com)  
609-460-3583 ext. 1083

Source: UroGen Pharma Ltd.